Filing Flows › Beam Therapeutics (BEAM) › Q1 2025
Beam Therapeutics (BEAM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Beam Therapeutics (BEAM) reported revenue of $7.5M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -75% from the quarter before.
Beam Therapeutics, Q1 2025: revenue $7.5M (+0.8% year over year), net loss $108M, operating cash flow −$104M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.5M | -75% | +0.8% |
| Operating profit | −$119M | — | — |
| Net earnings | −$108M | — | — |
| Operating cash flow | −$104M | — | — |
What changed
Revenue was $7.5M in Q1 2025, up 1% year over year and down 75% from the previous quarter.
Operating costs exceeded revenue by $119.3M, an operating margin of -1596.9%. Total costs grew 14% against revenue growth of 1%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $108.3M, wider than the previous quarter's $90.4M loss.
Operating cash flow was −$103.9M. Non-cash charges added back $5.5M of depreciation and $26.7M of share-based compensation. Working capital and other items used $27.8M. Capital expenditures of $3.1M exceeded it, leaving free cash flow of −$106.9M.
Questions
What was Beam Therapeutics' revenue in the first quarter 2025?
Beam Therapeutics (BEAM) reported revenue of $7.5M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -75% from the quarter before.
Source: Beam Therapeutics 10-Q on SEC EDGAR.